The Good: Tesla Tesla’s stock has gone absolutely ballistic in the last two years, with many detractors pointing to an unsustainable value compared to the sales Tesla were making. But Tesla’s first quarter report quieted critics, at least for now, after it beat Wall Street’s expectations on both cars delivered and cars manufactured. The stock moved up nearly 5% on the news. Perhaps the most significant development from the report is that all of the electric vehicles Tesla produced were Model 3 sedans and Model Y crossover SUVs. As Tesla pivots away from its luxury editions—it produced zero of its more expensive Model S and Model X SUVs—it opens up to a wider consumer base, providing optimism for some analysts. Tesla faced a slew of challenges in the first quarter which potentially limited its capabilities, ranging from a fire at a factory to parts shortages. Nonetheless, Tesla impressed analysts. The Other Good: AMC AMC has had a difficult time in the pandemic, as most entertainment related stocks have. First they lobbied for a government package that would keep them afloat, then they raised debt to make it through a year where theaters are reopening at limited capacity. This, combined with AMC’s week as a meme stock and movie studio’s doing dual release in theaters and on their streaming platforms, following AMC’s narrative has been anything but simple. But AMC got an upgrade today, sending the stock into the green, based on the numbers of the once-delayed blockbuster, Godzilla vs. Kong. The big monster battle, which, as you probably guessed, pits Godzilla against King Kong, earned $48.5 million over the Easter weekend, despite the fact that it was released for free at home to HBO Max subscribers. After a full year of weak box office reports, this was a roar back for the industry, causing some deserved confidence. The Ugly: Acadia Pharmaceuticals Acadia Pharmaceuticals, the neuroscience based biotech company, was dealt another blow today after the FDA rejected a label expansion of the drug pimavanserin. While the rejection was expected, analysts are pointing to the particularly dour FDA letter, which indicated that the company would have to do one or two more trials to advance its medication meant to aid those suffering from dementia. Acadia Pharmaceuticals had already fallen 45% earlier this month when it revealed the FDA had “identified deficiencies” in the company’s application. The biotech company is down another 14% today.